Vyvanse Use During Pregnancy
Vyvanse (lisdexamfetamine) can be continued during pregnancy when clinically necessary, as current evidence is largely reassuring regarding major congenital malformations and serious adverse outcomes. Since Vyvanse is a prodrug that converts to dextroamphetamine, the safety data for amphetamines applies directly to this medication 1.
Evidence-Based Safety Profile
The most recent 2024 American Journal of Obstetrics and Gynecology guidelines provide the framework for this recommendation 1:
Major Malformations
Amphetamines (including Vyvanse) do not appear to be associated with major congenital malformations, including cardiac malformations 1. The 2023 Massachusetts General Hospital National Pregnancy Registry study found no major malformations in infants exposed to lisdexamfetamine during the first trimester 2. A 2025 Danish population study of over 1 million births found no increased risk of neurodevelopmental disorders in offspring exposed to ADHD medications in utero 3, 4.
Possible Small Risks to Monitor
While the overall evidence is reassuring, there are some potential associations with small absolute risks:
Gastroschisis: Possible increased risk (aOR 3.0; 95% CI 1.2-7.4), but this is from one study with possible confounding, and the absolute risk remains extremely small given the baseline population prevalence of only 0.05% 1
Preeclampsia: Possible small increased risk (aRR 1.29; 95% CI 1.11-1.49), though other studies have not confirmed this association 1
Preterm birth: Possible small increased risk when stimulant use continues in the second half of pregnancy (aRR 1.30; 95% CI 1.10-1.55) 1. A 2025 Scandinavian study found this risk increased with longer duration of use, particularly with methylphenidate in late pregnancy 5
Important context: These risks appear small, and multiple studies have failed to replicate these findings, suggesting possible confounding by indication (untreated ADHD itself is associated with increased risks for spontaneous abortion and preterm birth) 1.
Clinical Decision-Making Algorithm
When to Continue Vyvanse:
- Moderate to severe ADHD where discontinuation would significantly impair maternal functioning
- Patient has been stable on lisdexamfetamine specifically (no compelling reason to switch medications if doing well) 3
- Benefits of treatment outweigh the small potential risks outlined above
Monitoring During Pregnancy:
- Blood pressure and heart rate at each prenatal visit 6
- Fetal growth monitoring (standard ultrasounds)
- Consider closer monitoring for preeclampsia signs given possible small association
- Dosing: Start 20-30 mg daily, titrate by 10 mg weekly to maximum 70 mg daily 1
Alternative Considerations:
- Methylphenidate has the most robust safety data and may be preferred for new users 3
- Non-pharmacologic approaches (Dialectical Behavior Therapy) can be considered as adjunctive treatment 1
- Bupropion is a non-stimulant alternative, though less effective for ADHD 1
Critical Caveats
The FDA label warns of potential fetal effects and advises patients to notify healthcare providers if they become pregnant 6. However, this reflects regulatory caution rather than definitive evidence of harm. The label also notes a pregnancy registry exists (1-866-961-2388) for monitoring outcomes 6.
Untreated ADHD carries its own risks: Discontinuing treatment can lead to worse mental health outcomes and significant functional impairments in the pregnant individual, which may negatively impact the developing fetus 1.
Confounding by indication is a major issue in observational studies—women with more severe ADHD (who are more likely to continue medications) may have inherently higher baseline risks 7.
Breastfeeding
Vyvanse passes into breast milk (Hale Lactation Risk Category L3) 1. The FDA label advises against breastfeeding while taking Vyvanse 6. However, one case report demonstrated successful breastfeeding with lisdexamfetamine use without observed infant side effects 8. If breastfeeding is pursued, monitor the infant carefully for irritability, insomnia, and feeding difficulties 1.
Bottom Line
Continue Vyvanse during pregnancy when maternal ADHD is moderate to severe and functional impairment would result from discontinuation. The evidence is largely reassuring, with no clear association with major malformations. The possible small increases in preeclampsia and preterm birth risk require monitoring but should not automatically preclude use when the medication is clinically necessary. This represents a shared decision-making conversation weighing small potential risks against the documented harms of untreated ADHD during pregnancy.